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ABSTRACT:b-Blockers reducemortalityandimprovesymptomsinpeoplewithheartdisease;however, currentclinically
available b-blockers have poor selectivity for the cardiac b1-adrenoceptor (AR) over the lung b2-AR. Unwanted b2-
blockade risks causing life-threatening bronchospasm and reduced efficacy of b2-agonist emergency rescue therapy.
Thus, current life-prolongingb-blockers are contraindicated in patients with both heart disease and asthma. Here, we
describeNDD-713 and -825, novel highlyb1-selectiveneutral antagonistswithgoodpharmaceutical properties that can
potentially overcome this limitation. Radioligand binding studies and functional assays that use human receptors
expressed inChinesehamsterovarycellsdemonstrate thatNDD-713and -825havenanomolarb1-ARaffinity>500-fold
b1-AR vs. b2-AR selectivity and no agonism. Studies in conscious rats demonstrate that these antagonists are orally
bioavailable and cause pronounced b1-mediated reduction of heart rate while showing no effect on b2-mediated
hindquarters vasodilatation. These compounds also have gooddisposition properties and showno adverse toxicologic
effects. They potentially offer a truly cardioselectiveb-blocker therapy for the large number of patientswith heart and
respiratory or peripheral vascular comorbidities.—Baker, J. G., Gardiner, S.M.,Woolard, J., Fromont, C., Jadhav,G. P.,
Mistry, S. N., Thompson, K. S. J., Kellam, B., Hill, S. J., Fischer, P. M. Novel selective b1-adrenoceptor antagonists for
concomitant cardiovascular and respiratory disease. FASEB J. 31, 3150–3166 (2017). www.fasebj.org
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b-Adrenoceptor (AR) antagonists (b-blockers) block cat-
echolamines from binding to b-AR, which reduces heart
rate (HR) and the force of contraction, thereby reducing
myocardial oxygen demand (1, 2). Randomized, placebo-
controlled clinical trials demonstrate mortality reductions
with b-blockers of 34 to 35% in patients with heart failure
and of 36 to 39% in patients with myocardial infarction
(3–7).b-Blockersare therefore recommendedforallpatients
with heart failure or a recent myocardial infarction, as well
as being first-line therapy for atrial arrhythmias andhaving
important roles in hypertension, thyrotoxicosis, portal hy-
pertension, migraine, glaucoma, and anxiety.
Bisoprolol (8) is one of the most b1-selective b-blockers
clinicallyavailable and, althoughoftencalled cardioselective,
has poor b1- vs. b2-selectivity (9–11). Unfortunately, this re-
sults in b2-AR blockade in the airways that risks, in suscep-
tible individuals, b2-mediated bronchospasm and reduced
effectiveness of life-saving b2-agonist bronchodilation ther-
apy (12). A meta-analysis of randomized controlled trials of
b-blockers in those with asthma reports a significant fall in
lung function [forced expiratory volume in 1 s (FEV1)], an
increase in symptoms, and attenuation of b2-agonist rescue
with cardioselective and nonselective b-blockers (13). Al-
though the average fall in lung function was greater with
nonselective agents, a.20%reduction in FEV1 still occurred
in 1 in 8 patients who received cardioselective b-blockers.
Other large, recentobservational studiesalso report thatboth
cardioselective and noncardioselective b-blockers result in
reduced lung function in the general population [that
recovers on cessation of b-blockers (14)] and in those with
asthma when using b-blocker eye drops (15). A further ob-
servational study found that nonselective, but not car-
dioselective, b-blockers increase the risk of moderate and
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severe asthma exacerbations (16). In addition, catastrophic
outcomes have been also reported (17–23). Taken together,
these studies suggest that b1-selective (cardioselective)
b-blockers are better than nonselective b-blockers, but that
current cardioselective agents still pose a risk to those with
asthma. b-Blockers are therefore contraindicated in patients
with asthma (24).
Patients with chronic obstructive pulmonary disease
(COPD) have a high risk of heart disease: 40% of thosewho
suffer fromCOPDalsohaveheartdisease (25)andtheyhave
high cardiovascular mortality (26, 27). As up to 50% of pa-
tients with COPD also have significant airway reversibility
(improvement in lung functionwithb-agonists), they are at
risk of bronchospasm from b-blockers (28, 29). b-Blockers
reduce lung function in COPD, often by more than the 5 to
10% that is suggested by the American Thoracic Society/
European Respiratory Society as important in COPD, but
this is often well tolerated [for full details, see Baker and
Wilcox (7)]. There are no randomized placebo-controlled
studies of b-blockers in patients with heart disease and
COPD, but currently, the number of observational studies
with favorable or neutral outcomes outweigh those with
detrimental outcomes (7, 30–32). Because of high cardio-
vascular mortality, current guidelines recommend trying
b-blockers under carefulmedical supervision for thosewith
heartdiseaseandCOPD,althoughthis isnotwithoutpatient
risk and causes significant clinician anxiety (33, 34).
Highly b1-selective antagonists would overcome the
problems that are associated with unwanted b2-blockade.
CGP20712A and LK204-545 are the twomost highly b1-
selective b-blockers reported to date, but neither was
developed into clinical drugs (35, 36).
Partial agonism [intrinsic sympathomimetic activity
(ISA)]alsovaries significantlybetweenb-blockers.Thiswas
once consideredbeneficial: Partial agonistswouldblockHR
surges from adrenaline but also provide increased basal
tone inheart failureandreduce thechanceofbronchospasm
(12); however, partial agonism has been proven to be det-
rimental. In heart failure, b-blockers with little or no ISA
prolonged life (3, 4), whereas thosewith higher ISA had no
benefit or were detrimental (37, 38). Post–myocardial in-
farction, b-blockers without ISA reduced mortality (5, 6),
whereas those with ISA did not (39, 40). Lowering HR is
required for increased survival (41). LK204-545 has signifi-
cant b1-partial agonism (42).
Thus, highly b1-AR–selective antagonists, devoid of
partial agonism, could overcome unwanted b2-blockade,
increasing the safety of b-blockers in those with COPD
and peripheral vascular disease and potentially allowing
treatment in thosewithasthma.This studyaimedtodevelop
highly b1-selective orally bioavailable b-blockers with no
agonism or off-target effects that also had pharmacokinetic
(PK) properties suitable for once daily oral dosing.
MATERIALS AND METHODS
Study approval
Cardiovascular monitoring procedures were carried out with
approval of the University of Nottingham Ethical Review
Committee under Home Office Project and Personal License
Authority (to S.M.G. and J.W.).
NDD compounds
NDD-713 {4-[2-[[(2S)-3-[[(2R)-2-[[(cyclopropylmethoxy)methyl]-
2,3-dihydro-1,4-benzodioxin-6-yl]oxy]-2-hydroxypropyl]
amino]ethoxy]benzamide; Chemical Abstracts Survey (CAS)
registry no.1392488-35-5} and NDD-825 {5-[2-[[(2S)-3-[[(2R)-2-
[[(cyclopropylmethoxy)methyl]-2,3-dihydro-1,4-benzodioxin-
6-yl]oxy]-2-hydroxypropyl]amino]ethoxy]-2,3-dihydro-1H-
isoindol-1-one; CAS registry 1392488-42-4} were prepared
and characterized as previously described (43).
Cell culture
Chinese hamster ovary (CHO) cells that stably express human
b1-ARs (CHO-b1: 1146 fmol/mg protein), human b2-ARs
(CHO-b2: 466 fmol/mg protein), or human b3-ARs (CHO-b3:
790 fmol/mgprotein)were grownaspreviouslydescribed (11).
Human bronchial smooth muscle cells were obtained from
Lonza (Basel, Switzerland) and grown in manufacturer media.
Rat b-AR binding experiments (DNA from cDNA Resource
Centre, Bloomsburg, PA, USA) were conducted by using
transiently transfected CHO cells (44).
3H-CGP12177 whole-cell binding
Confluent cells were examined (96-well plates, 2 h incubation
at 37°C) as previously described (11) with 3H-CGP12177 at
0.43–3.03 nM. Propranolol (10 mM) defined nonspecific binding.
Kd values were derived from IC50 values by using the Cheng-
Prusoff equation as previously described (11). Kd values for
3H-CGP12177, which were obtained from saturation binding
in this study, were 0.49 6 0.02 nM (n = 14) for human b1-AR;
0.28 6 0.01 nM (n = 14) for human b2-AR; 0.24 6 0.03 nM
(n = 7) for rat b1-AR, and 0.256 0.04 nM (n = 7) for rat b2-AR.
3H-cAMP accumulation
Confluent cells were examined (24-well plates, 5 h incubation at
37°C) as described in Baker (45). Antagonist Kd values were calcu-
lated from a rightward shift of the agonist concentration response
curvebyusing theGaddumequationaspreviouslydescribed (46).
cAMP response element–secreted placental
alkaline phosphatase reporter gene assay
cAMP response element (CRE)–secreted placental alkaline
phosphatase (SPAP) productionwasmeasured in confluent cells
(96-well plates, 5 h incubation at 37°C) as described in Baker (46).
This assay is a sensitive measure of both cAMP and ERK1/2
MAPK pathways (47).
Direct measurement of MAPK stimulation
MAPK stimulation was examined by using the AlphaScreen
Surefire ERK1/2 T202/Y204 assay kit from TGR Biosciences
(PerkinElmer, Waltham, MA, USA), which gives a direct quan-
titative readout of ERK1/2 (p42/44) MAPK phosphorylation.
Confluent cells (half-well 96-well plates) were serum starved for
24h, then theassaywasperformedpermanufacturer instructions
(5- and 10-min incubations at 37°C: ligand concentrations of 3
HIGHLY b1-SELECIVE b-ADRENOCEPTOR ANTAGONISTS 3151
 Vol.31,  No.7 , pp:3150-3166, October, 2017The FASEB Journal. 128.243.38.220 to IP www.fasebj.orgDownloaded from 
and 10 mM). Phorbol 12,13-dibutyrate (1 mM) was used as a
positive control.
Duration of ligand binding
A method that involved ligand washout was used as de-
scribed (44). Cells were incubated with either competing li-
gand and 3H-CGP12177 for 2 h (control plate), or competing
ligand alone for 2 h (duration plate). After 2 h, the control
plate was processed while the duration plate was washed,
and 3H-CGP12177 alone was added to wells and incubated
for a second 2 h before processing. Long-acting ligands that
do not dissociate from the receptor should result in similar
3H-CGP12177 binding to control. Shorter-acting ligands that
were removed and/or that continued to dissociate during the 2-h
3H-CGP12177 incubation would result in more 3H-CGP12177
binding than control and, thus, an apparent rightward shift of the
concentration response curve. Relative measures of ligand dura-
tion of binding are indicated by the degree of rightward shift
of displacement curves (44).
In vitro receptor selectivity profiling
Receptor selectivity of reference compounds LK204-545 and
CGP20712A (10 mM), and NDD-713 (4.8 mM) and NDD-825
(2.4 mM; concentrations approximately 400-fold greater than b1
Kd), were examined. Ki (inhibition constant) was calculated by
using the Cheng-Prusoff equation from the mean of duplicate
determinations in cell-based receptor radioligand-binding as-
says. Cerep in vitropharmacology profiling servicewas used (see
the Supplemental Data for a list of the assays used).
Aqueous solubility
NDD-713.HCl and -825.HCl were added to either aqueous phos-
phate buffer (pH 6.5) or 0.01 M aqueous HCl (pH ;2) at final
DMSO concentrations of 1%. Samples were analyzed by nephe-
lometry to determine solubility ranges (48). Studies were carried
out by the Centre for Drug Candidate Optimisation (CDCO;
Monash University, Melbourne, VIC, Australia).
Lipophilicity
Octanol–water partition coefficient values (logD) of NDD-713
and -825 were estimated as described in Lombardo et al. (49)
by correlation of the chromatographic retention properties of
compounds against the characteristics of standard com-
pounds with known partition coefficient values. Studies were
carried out by CDCO.
Permeability
CaCo-2 cells were grown in Transwell permeable supports,
and confluency was assessed by transepithelial electrical resis-
tance measurements (.270 V/cm2) and by unidirectional per-
meability (apical-basolateral) of the low- and high-permeability
reference compounds, 14C-mannitol and 3H-propranolol.
NDD-713.HCl and -825.HCl (20 mM in HBSS that contained
20 mM HEPES, pH 7.4) were transferred to the donor com-
partment of Transwell plates and the acceptor compartments
were filled with blank HBSS. Permeability was determined
over 90 min by sampling both compartments. Quantitation of
compound concentrations in donor and acceptor samples was
by liquid chromatography–mass spectrometry (LC-MS; lower
limit of quantification, 0.5–1.5 ng/ml), and for 14C-mannitol and
3H-propranolol, by liquid scintillation counting. Apparent per-
meability coefficients (Papp) were calculated as follows:
Papp (cm/s) = dQ/dT3 1/(C0 3 A), where dQ/dt = apparent
steady-state transport rate (mmol/s); C0 = initial concentration in
the chamber (mmol/cm3); and A = surface area of CaCo-2
monolayer (0.3cm2). Efflux ratioswere calculated as the ratio of
mean Papp values in B→A and A→B directions. Studies were
carried out by CDCO.
Metabolic stability
NDD-713.HCl and -825.HCl were incubated (0.02, 0.1, or
0.5 mM at 37°C, 120 min) with human (XenoTech, Kansas
City, KS, USA) or rat liver microsomes (BD Biosciences, Brea,
CA, USA) at 0.4 mg/ml protein concentration. Metabolic
reaction was initiated by addition of NADPH-regenerating
system or NADPH-regenerating system with uridine di-
phosphate glucuronic acid. Samples were quenched at time
points by acetonitrile addition. Control samples, which
contained neither NADPH, nor uridine diphosphate glu-
curonic acid, were monitored for degradation. Compound
concentrations were determined by ultraperformance LC-MS
(UPLC-MS) relative to calibration standards that were pre-
pared in quenched liver microsomes and fitted to exponential
decay functions to determine first-order rate constants (k) for
substrate depletion. These were used to calculate in vitro in-
trinsic clearance (CLint) values: CLint = k/microsomal protein
content (0.4 mg protein/ml). Metabolic stability assays that
used rat liver cytosol (BD Biosciences), human cryopreserved
hepatocytes, or rat hepatocytes were carried out similarly.
Average viable cell concentrations were determined by Try-
pan Blue exclusion methods (in the absence of test com-
pounds). Studies were carried out by CDCO.
Metabolism
NDD-713.HCl and -825.HCl (2 mM) and cytochrome P450
(P450) reference substrates (see Supplemental Data for full
details) were incubated (37°C) with selected recombinant
human P450 isoforms (CYP1A2, CYP2A6, CYP2B6, CYP2C8,
CYP2C9, CYP2C19, CYP2D6 CYP2E1, and CYP3A4) in het-
erologously expressed P450 Supersomes (BD Biosciences)
that were suspended in 50 M Tris-HCl buffer (pH 7.4; for
CYP2C9) or 100 mM phosphate buffer (pH 7.4; for the other
isoforms) at final P450 concentrations of 85 pmol/ml. Reac-
tions were initiated by additions of an NADPH-regenerating
system and quenched at time points over 60 min (refer-
ence probes) or 120 min (test compounds) by acetonitrile.
Quenched samples were centrifuged and supernatants were
collected. NDD-713, -825, and probe metabolites were de-
termined by UPLC-MS relative to calibration standards
prepared in quenched matrix, and %substrate that remained
was calculated relative to the initial sample concentration.
The %substrate that remained vs. time was fitted to expo-
nential decay functions to determine the pseudo first-order
rate constant (k/min) for substrate depletion. These were
normalized to P450 concentrations (pmol/ml) to obtain in vitro
CLint values: CLint, in vitro (ml/min/pmol P450) = [k (min
21)/P450
concentration (pmol/min)]3 1000. Studies were carried out
by CDCO.
P450 inhibition
Concentrations of NDD-713.HCl and -825.HCl (0.25–20 mM)
were incubated in triplicate (37°C for 4–40 min) with
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substrates specific for individual P450 isoforms (see Supple-
mental Data for full details) in human liver microsomes
(batch 34689 for CYP1A2 and CYP3A4; batch 0910251 for
CYP2C9, CYP2C19, and CYP2D6) at protein concentra-
tions of 0.4 mg/ml (CYP1A2, CYP2C9, CYP2D6 and
CYP3A4/5) or 1.0 mg/ml (CYP2C19) and a total organic sol-
vent concentration,1%. Reaction was initiated by addition of
NADPH-regenerating system and sampleswere quenched by
addition of ice-cold acetonitrile, which contained 0.15 mg/ml
diazepam as an internal standard, before determination of the
concentration of specific metabolites by LC-MS. Compound
IC50 values (and positive control) for each P450 isoform was
assessed according to %reduction in formation of the specific
metabolite (maximal metabolite formation occurring in the
absence of inhibitor). IC50 was taken as the concentration that
caused a 50% reduction of the metabolite formed relative to
the maximal extent of formation. Control samples were
included to confirm that the LC-MS assay was not affected by
test compounds (and potential metabolites). Studies were
carried out by CDCO.
Protein binding
Protein binding of 1 mMNDD-713.HCl and -825.HCl in human
and rat plasma, aswell as human livermicrosomes,was assessed
by using the ultracentrifugation technique. Frozen human
plasma (Australian Red Cross Blood Service, Melbourne, VIC,
Australia) and rat plasma (male Sprague-Dawley rats; Charles
River, Margate, Kent, United Kingdom) were thawed at 37°C.
Human liver microsomes (XenoTech) were suspended in 0.1 M
phosphatebuffer (pH7.4) atprotein concentrationsof0.4mg/ml.
Samples were collected immediately as stability reference con-
trols. Spikedplasma samples (but notmicrosome samples) were
TABLE 1. Afﬁnity and selectivity of existing clinically used and novel b-AR ligands
Compound
Human b1-AR Human b2-AR Human b1 vs. b2 selectivity
Log Kd n Log Kd n Kd,b2/Kd,b1
Bisoprolol 27.96 6 0.03 16 26.33 6 0.03 15 42.7
Carvedilol 29.19 6 0.04 10 29.83 6 0.06 5 0.23
CGP20712A 28.76 6 0.03 94 25.62 6 0.02 66 1380
ICI118551 26.66 6 0.02 88 29.17 6 0.02 66 0.003
LK204-545 28.17 6 0.07 15 25.30 6 0.04a 11 741
NDD-713 27.82 6 0.03 27 25.05 6 0.03a 23 589
NDD-713.HCl 27.70 6 0.04 24 25.01 6 0.04a 18 490
NDD-825 28.28 6 0.05 20 25.27 6 0.03a 16 1023
NDD-825.HCl 28.17 6 0.03 21 25.34 6 0.05a 16 676
Rat b1-AR Rat b2-AR Rat b1 vs. b2 selectivity
Compound Log Kd n Log Kd n Kd,ratb2/Kd,ratb1
Bisoprolol 28.24 6 0.04 5 25.82 6 0.04 5 263
Carvedilol 29.44 6 0.07 6 29.72 6 0.06 6 0.52
CGP20712A 29.12 6 0.07 6 25.15 6 0.06 6 9322
ICI118551 26.89 6 0.04 6 29.26 6 0.06 6 0.003
LK204-545 28.36 6 0.05 6 24.81 6 0.04a 6 3548
NDD-713 28.07 6 0.09 5 24.73 6 0.08a 5 2188
NDD-825 28.37 6 0.02 6 24.88 6 0.02a 6 3090
Log Kd values and ligand selectivities as determined from
3H-CGP12177 whole-cell binding in stable
cells lines that express human receptors (CHO-b1 and CHO-b2 cells) or in CHO cells that are transiently
transfected with the b1- or rat b2-AR. Values shown are means 6 SEM of n separate experiments. Thus,
bisoprolol was 42.7 times more selective for human b1-AR than human b2-AR, whereas carvedilol was 4.4
times more b2-selective.
aApparent log Kd values: these are reported when the maximum concentration
of competing ligand was not able to inhibit all of the speciﬁc binding (e.g., NDD-825 and -713 in Fig. 2B).
The apparent Kd value given is therefore assuming that all speciﬁc binding would be inhibited by a higher
concentration of competing ligand.
TABLE 2. Afﬁnity and selectivity of existing clinically used and novel b-AR ligands as determined from antagonism of cimaterol-induced
3H-cAMP accumulation in CHO-b1, CHO-b2, or CHO-b3 cells
Compound
Human b1-AR Human b2-AR Human b3-AR b1 vs. b2 selectivity
Log Kd,b1 n Schild slope n Log Kd,b2 n Log Kd,b3 n Kd,b2/Kd,b1
Bisoprolol 28.60 6 0.03 15 0.97 6 0.03 5 26.76 6 0.03 13 25.65 6 0.06 5 69
Carvedilol 29.75 6 0.12 12 1.29 6 0.09 4 210.62 6 0.08 4 28.54 6 0.18 3 0.13
Nebivolol 29.28 6 0.08 22 1.15 6 0.03 5 27.91 6 0.09 11 26.35 6 0.06 9 23
CGP20712A 29.64 6 0.03 15 1.03 6 0.03 5 26.02 6 0.03 8 25.47 6 0.04 5 4169
NDD-713 28.52 6 0.03 12 1.06 6 0.03 4 25.44 6 0.03 4 25.47 6 0.08 3 1202
NDD-825 28.99 6 0.05 9 1.04 6 0.02 3 25.75 6 0.06 4 25.72 6 0.08 7 1738
The Schild slope is that obtained in CHO-b1 cells from the rightward shift of the cimaterol dose-response curve by 3 different concentrations
of antagonist in the same experiment (e.g., Fig. 3) where a value of 1 represents competitive antagonism. The afﬁnity of most ligands at b2-AR and
b3-AR was too low to allow a Schild plot to be constructed. Values shown are means 6 SEM of n separate experiments.
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incubated at 37°C for 1 h. Aliquots of the spiked matrix were
spun (223,000 g, Beckman rotor type 42.2Ti; Beckman
Coulter, Brea, CA,USA) for 4.2 h at 37°C to separate proteins.
Noncentrifuged control samples were maintained at 37°C.
After ultracentrifugation, supernatant was stored frozen, to-
gether with noncentrifuged samples at220°C. NDD-713.HCl
and -825.HCl concentrations of noncentrifuged matrix and
protein-free supernatant were determined by UPLC-MS rel-
ative to calibration standards prepared in the respective ma-
trices. Total concentration (Ctotal) was the average measured
concentration in centrifuged samples maintained at 37°C, and
unbound concentration (Cunbound) was the average measured
concentration in protein-free supernatants from centrifuged
samples (n = 3). The compound unbound fraction (fu) was
calculated: fu = Cunbound/Ctotal. Compound degradation was
assessed by comparing concentrations in noncentrifuged
plasma samples that were incubated at 37°C with concentra-
tions measured in the t = 0 noncentrifuged samples. Plasma
protein binding values were estimated by correlation of their
chromatographic retention properties on human albumin
columns against those of standard compounds with known
protein binding values as previously described (50). Studies
were carried out by CDCO.
PK analysis
NDD-713.HCl and -825.HClwere intravenously administered
after overnight food withdrawal to male Sprague-Dawley rats
(weighing 241–289 g) at 2 or 6 mg/kg (formulated at 1 mg/ml
in aqueous vehicle that contained 5% DMSO and 5% glucose)
or 20 mg/kg (formulated at 5.3 mg/ml in aqueous vehicle that
contained 5% DMSO in 0.2 M Captisol; Ligand Pharmaceuti-
cals, Inc., San Diego, CA, USA) as a 10-min constant-rate
infusion (1 ml/rat, 3 rats/dose level) and orally at 2, 10, or
20 mg/kg (formulated at 0.4–2.3 mg/ml in aqueous vehicle
that contained 0.5% hydroxymethylcellulose, 0.5% benzyl
alcohol, and 0.4% Tween-80) by gavage (1.0 ml/rat, 3 rats/
compound). Arterial blood was collected for 24 h directly
into borosilicate vials (at 4°C) that contained heparin,
Complete (a protease inhibitor cocktail; Sigma-Aldrich,
St. Louis, MO, USA), potassium fluoride, and EDTA to
minimize potential ex vivo degradation of compounds in
blood and plasma samples. Blood samples were centrifuged,
supernatant plasma was removed, and plasma concentra-
tions of compounds were determined by LC-MS. Bio-
availability was calculated relative to the mean AUC value
for each compound observed after intravenous dosing at
2 mg/kg. Studies were carried out by CDCO.
In vivo pharmacology
Adult male Sprague-Dawley rats, weighing 3002400 g, were
chronically instrumented with pulsed Doppler flow probes
and intravascular catheters for cardiovascular monitoring
and drug administration in a 2-stage surgical protocol as
described (51). Surgery was performed under general anes-
thesia (fentanyl and medetomidine, 300 mg/kg of each, i.p.),
with reversal and postoperative analgesia provided by ati-
pamezole (1 mg/kg, s.c.) and buprenorphine (0.02 mg/kg,
s.c.). Experiments were performed with animals that were
fully conscious and unrestrained in home cages and given
free access to food and water. Cardiovascular variables were
recorded by using a customized, computer-based system
(InstrumentDevelopment Engineering Evaluation,Maastrich
Instruments Bv, Maastrich, The Netherlands) with raw data
sampled every 2 ms. Hindquarters vascular conductance
(HQC) was calculated as Doppler shift (flow)/mean arterial
pressure. Throughout, atropinemethyl nitrate (1mg/kg/h)was
infused (0.4 ml/h) continuously to inhibit vagally induced HR
changes.
Intravenous administration of b-blocker
Starting at least 1 h after atropine infusion began, rats were in-
travenously administered 3 doses of isoprenaline [12, 40, and
120 ng/kg/min, 3-min infusions (0.15 ml/min), 20–30 min be-
tween doses], before a b-blocker was administered as an intra-
venous bolus (2 mg/kg, 0.1 ml, except CGP20712A, which was
200mg/kg; in saline) thatwasmaintainedby continuous infusion
for 90min (1mg/kg/h, 0.4ml/h, exceptCGP20712A,whichwas
100 mg/kg/h). Isoprenaline infusions were repeated during the
Figure 1. Chemical structures of b1-selective b-blockers.
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final 60 min of b-blocker infusion and 3–4 and 23–24 h after
b-blocker infusions finished.
Oral administration of increasing doses of NDD-825.HCl
Experiments ran over 3 consecutive days. Lightly sedated rats
(propofol at 0.1–0.2ml of 10mg/ml, i.v.) thatwere instrumented
for cardiovascularmonitoringwere administered an oral dose of
NDD-825.HCl (1mg/kgond1, 3mg/kgond2, 10mg/kgond3;
10 ml/kg in water) by oral gavage. Each day, responses to iso-
prenaline infusions were monitored before and at 0.5–1.5 and
3–4 h after oral NDD-825.HCl administration.
Isoprenaline responses shown are absolute values forHR and
HQC before the first dose of isoprenaline (baseline) and during
the third minute of infusion of each dose. Values at baseline and
during the highest isoprenaline dose were tested for statistical
significance by using a nonparametric ANOVA test with cor-
rection for repeatmeasures [Quade test (52)]. A value of P, 0.05
was taken as significant.
Cytotoxicity
Human Caucasian hepatocyte carcinoma cells (HepG2; Euro-
pean Collection of Cell Cultures, Salisbury, United Kingdom)
weregrowninaccordancewith theirguidelinesbyusingDMEM.
Cells at a density of 30,000 cells/well in 96-well plates were in-
cubated overnight (37°C, 5% CO2 atmosphere). Medium was
then removed and replaced with DMEM that contained control
or compounds (1, 10, and100mM;n=2per concentration) for 24h
beforeadditionof 100ml/well ofCellTiter-GloReagent (Promega,
Madison, WI, USA) for ATP measurement and shaken to induce
cell lysis. Luminescence was quantified on an AnalystAD plate-
reader (Molecular Devices, Sunnyvale, CA, USA). Thioridizine
(known HepG2 cytotoxicity) was used as positive control. Study
was carried out by BioFocus DPI (Saffron Walden, United
Kingdom).
hERG inhibition
Binding to the hERGpotassium channel (recombinant protein
from HEK293 cells) was examined by using 3H-astemizole
radioligand binding assays [Cerep (53)] by measuring the
displacement of radioligand binding from the channel by
10 mM NDD-713 and -825. In addition, the potential of the
compound to inhibit hERG channels was tested by using
an automated patch-clamp electrophysiological assay (Bio-
Focus, Cambridge, United Kingdom; using the Precision
hERG-HEK recombinant cell line from on an Ion Works
Quattro automated electrophysiology platform; Millipore,
Billerica, MA, USA). The antiarrhythmic research drug E4031
was used as positive control (IC50 = 83 nM).
Ames genotoxicity
Ames fluctuation assays were performed by using Salmonella
typhimurium strains TA98, TA100, TA1535, and TA1537 to detect
frame-shifts and base substitutions that led to missense muta-
tions in liquid culture in 384-well plates. Bacterial plates were
incubated with serially diluted NDD-713 and -825 solutions for
96h, andbacterial growthwasmeasured spectrophotometrically
by using a pH color-change indicator in response to bacterial
growth acidification. Assays were conducted with or without
metabolic activation via addition of rat liver S9 frac-
tion. Bacteriocidal or bacteriostatic effects were assessed by
using a bacterial cytotoxicity assay that was conducted in par-
allel with Ames fluctuation assays. Reference compounds were
2-aminoanthracene, 9-aminoacridine, quercetin, streptozotocin
(genotoxicity), and mitomycin C (bacterial cytotoxicity). Study
was carried out by Cerep (Celle L’Evescault, France).
Seven-day oral dose range rat toxicity study
Male Crl:CD rats (9 wk old, weighing 316.8–349.4 g on d 1;
Charles River)were administered 1 oral dose ofNDD-825.HCl in
water that contained 0.5% (w/v) hydroxypropylmethylcellulose
K15M,0.5% (v/v)benzyl alcohol, and0.4% (v/v)Tween-80at 20,
90, or 300mg/kg at a dose volume of 10ml/kg for 7 consecutive
days (4 animals per group). Blood samples were collected before
and at time points during the 24 h that followed for bioanalysis.
Animals were monitored for adverse clinical signs and body
weight. Terminal blood samples were taken for clinical chemis-
try, and organswere harvested formicroscopic examination (see
Supplemental Data for full details). Three additional male rats
per group received NDD-825.HCl on d 1 only to collect blood
samples for plasma bioanalysis of compound toxicokinetics.
NDD-825was quantifiable in plasmaof all animals up to 8 h after
dose administration; tmax occurred between 2 and 8 h after dos-
ing. Systemic exposure toNDD-825 in terms ofCmax increased in
approximate proportion with increasing dose, whereas for the
same dose increase, AUC0-t increased in a supraproportional
Figure 2. Inhibition of 3H-CGP12177 whole-cell binding in
response to CGP20712A, ICI118551, NDD-713, and NDD-825
in CHO-b1 (A) and CHO-b2 (B) cells. Nonspeciﬁc binding was
determined by 10 mM propranolol. Data points are means 6
SEM of triplicate determinations, and the concentrations of 3H-
CGP12177 present in these experiments was 0.89 nM. These
single experiments are representative of 20 (A) and 16 (B)
separate experiments.
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manner across the entiredose range.Overall, for a 15-fold increase
in dose from20 to 300mg/kg/d,AUC0-t andCmax increased 31.4-
and 12.4-fold, respectively. After repeat daily oral administration
of NDD-825 for 7 d, systemic exposure in terms of both Cmax and
AUC0-twascomparable to thatond1at eachrespectivedose level.
Study was carried out by Aptuit (Verona, Italy).
Calculation of selectivity indices
Selectivity indices (SIs) forbisoprolol in termsof receptor binding
(SI1; Supplemental Eq. 1) and receptor occupancy (SI2; Supple-
mental Eq. 2) were determined on the basis of the following pa-
rameters: Kd values at the human bARs from
3H-CGP12177
whole-cell binding (Table 1) for SI1a; Kd,b values from
antagonism of cimaterol-induced 3H-cAMP accumulation
(Table 2) for SI1b; and Cssf (at 10 mg/d p.o.) = 87.3 nM (23). SI2
values forNDD-713 and -825were estimated similarly (using SI1a
data) and assuming that as the bisoprolol dose (10 mg/d, p.o.)
required to lower exercise-induced HR is 35-fold over Kd (biso-
prolol Cssf/Kd,b1AR = 35) (23), a similar 35-fold-higher dose of
NDD-713 and -825would also be required. In vivopharmacologic
responses in humans (Eb-AR) were calculated for both b-ARs by
using Supplemental Eq. 3,whereEb1-AR andEb2-AR refer to effects
on exercise HR and on FEV1 under steady-state conditions after
drug administration, respectively. Supplemental Eq. 3 is based
(23, 54) on a ternary complex model (Supplemental Eqs. 4–6) of
agonist [A], receptor [R], transducer element [T], antagonist [B],
total receptor [R0], and transducer [T0] concentrations arebasedon
Supplemental Eqs. 7 and 8. The following values (23, 54) for b1-AR
Figure 3. 3H-cAMP accumulation in response to cimaterol in the absence or presence of bisoprolol (A), NDD-713 (B), and NDD-
825 (C) in CHO-b1 and CHO-b2 cells. Bars represent basal
3H-cAMP accumulation and accumulation in response to 10 mM
isoprenaline or b-blocker alone. Data points are means 6 SEM of triplicate determinations, and these single experiments are
representative of 5 (A), 4 (B), and 3 (C) separate experiments in each case.
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were used for the analysis: Eb-AR,max = 35%, KDA = 2 mM, and
[A] = 0.02mM.Forb2-AR,weusedEb-AR,max = 50%,KDA=3mM,
and [A] = 0.01 mM. The values (23, 54) used for the analysis of
exercise HR were KDAR = 0.64 nM, [R0] = 0.29 nM, and [T0] =
700 nM. The corresponding values (23, 54) used for the analysis
of FEV1 were KDAR = 2.6 nM, [R0] = 1.1 nM, and [T0] = 2.6 mM,
respectively. SI values in terms of in vivo human pharmacologic
response were calculated by using Supplemental Eq. 9.
RESULTS
As LK204-545 is ab1-selective ligand,we startedwith des-
cyanoanalogs of LK204-545 (55), andaftermany iterations
of multiparameter lead optimization, NDD-713 and -825
were the two compounds with the best overall perfor-
mance (Fig. 1) (43).
Molecular pharmacology of NDD-713
and -825
Affinity and duration of action
Ligandaffinity for humanb1- andb2-ARwas assessed first
by radioligand binding (Fig. 2). CGP20712A was a highly
b1-selective ligand (1380-foldb1-selective) and ICI118551 a
highly b2-selective ligand (333-fold b2-selective), whereas
current clinically used b-blockers had relatively poor se-
lectivity in comparison (Fig. 2 and Table 1). NDD-713 and
-825 both had high b1-affinity but poor b2-affinity (Fig. 2
and Table 1). At human b3-AR, NDD-713 and -825 af-
finity was so low that accurate measurements were not
possible. Affinities of compounds for rat b1- and b2-AR
were also determined by using transiently transfected
cells (Table 1).
Ligand affinity was also assessed in a functional
assay by examining the ability of ligands to in-
hibit cimaterol-induced 3H-cAMP accumulation re-
sponses (Fig. 3 and Table 2). Cimaterol is a stable
b-agonist—less susceptible to degradation over 5 h at
37°C than adrenaline or noradrenaline—that is active
across all 3 b-AR subtypes and that activates high-
affinity catecholamine conformation of the b1-AR
(42, 55). NDD-713 and -825 readily inhibited b1-
mediated cimaterol-induced responses but not b2-
or b3-mediated responses, which confirmed high
human b1-affinity and high b1-selectivity over b2- and
b3-ARs.
Finally, the ligand affinity for human b2-AR was also
determined in the more native environment of human
bronchial smooth muscle cells. Here, cimaterol-induced
3H-cAMPwas readily inhibitedwith ICI118551 but poorly
inhibited by CGP20712A, NDD-713, and -825 (Table 3).
Thus, NDD-713 and -825 had poor affinity for native
b2-ARs in these airway cells.
To assess whether b1-AR–antagonist interactions
were competitive, Schild plots (dose ratio21 vs. ligand
TABLE 3. Afﬁnity values obtained for ligands in human bronchial
smooth muscle cells (that natively express b2-AR) and in CHO-b2 cells
that stably express a transfected human b2-AR determined from
antagonism of cimaterol-induced 3H-cAMP accumulation
Antagonist
Human bronchial
smooth muscle cells CHO-b2 cells
Log Kd n Log Kd n
CGP20712A 26.06 6 0.08 4 26.02 6 0.03 8
ICI118551 29.51 6 0.13 4 29.65 6 0.03 6
NDD-713 25.47 6 0.05 4 25.44 6 0.03 4
NDD-825 25.87 6 0.11 4 25.75 6 0.06 4
Log Kd values shown are means 6 SEM of n separate experiments.
Figure 4. Inhibition of speciﬁc 3H-CGP12177 whole-cell
binding in CHO-b1 cells in response to bisoprolol (A), NDD-
713 (B), and -825 (C), with the control curve (solid circles)
and after washout of the competing b-blocker (open circles) as
described in Materials and Methods. Nonspeciﬁc binding
was determined by 10 mM propranolol. Data points are
means 6 SEM of triplicate determinations, and the concentra-
tions of 3H-CGP12177 present in these experiments were 0.81 nM
(A), 0.96 nM (B), and 0.74 nM (C). These single experiments
are representative of 4 (A), 9 (B), and 8 (C) separate
experiments.
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concentration) (56) were constructed from experi-
ments with 3 different concentrations of antagonists
(Fig. 3). A slope value of 1 represents competitive an-
tagonism and this was observed with all antagonists
(Table 2). The affinity of NDD-713 and -825 was too
low for this to be determined at b2- and b3-ARs.
An indication of duration of receptor occupancy was
sought by using a washout technique (44) where ligand
residence time is indicated by a rightward shift of the
washout curve relative to control (Fig. 4 and Table 4).
Carvedilol hada long residence time (control andwashout
curves are similar; log shift of 0.3=2-fold),which indicated
no b1-AR dissociation. In contrast, bisoprolol was read-
ily washed out (rightward log shift of 2.7; 501-fold),
which indicated significant ligand dissociation. NDD-713
and -825 had intermediate residence times (Fig. 4 and
Table 4).
Intrinsic efficacy
Ligand efficacy was initially assessed at the primary
Gs-cAMP pathway. Carvedilol and nebivolol were
weak partial b1-AR agonists, stimulating maximum
responses of 15.26 1.0% (n = 20) and 5.06 0.8% (n = 4),
respectively, of that with isoprenaline (similar to pre-
vious reports) (51). LK204-545 stimulated a response
that was 70.1 6 2.5% (n = 3) that of isoprenaline. No
3H-cAMP responses were observed with bisoprolol,
CGP20712A, NDD-713, or -825 (Fig. 5A). In other sig-
naling pathways, carvedilol and LK204-545 stimu-
lated CRE-SPAP production (a sensitive readout of
both cAMP and ERK1/2 MAPK) that was 31.2 6 2.8
and 79.3 6 2.7% (n = 5), respectively of the isoprenaline
maximum, whereas no responses were observed with
bisoprolol, CGP20712A, nebivolol, NDD-713, or -825
(Fig. 5B). Similarly, no agonist responses were ob-
served when directly measuring ERK1/2 phosphory-
lation (Fig. 5C).
Previous studies that examined responses in the parent
cell line CHO-CRE-SPAP cells (i.e., cells without the
transfected receptor) have demonstrated that there is no
endogenous b-AR present in these cells. There were no
TABLE 4. Relative duration of binding of existing clinically used and
novel b-AR ligands as determined from 3H-CGP12177 whole-cell
binding in CHO-b1 cells
Compound
Human b1-AR
Log shift n
Bisoprolol 2.70 6 0.18 4
Carvedilol 0.31 6 0.06 5
CGP20712A 1.35 6 0.04 28
ICI118551 1.64 6 0.07 24
Nebivolol 0.26 6 0.07 3
LK204-545 2.06 6 0.08 6
NDD-713 1.75 6 0.08 9
NDD-825 1.62 6 0.11 8
The log shift given is the measure of the rightward shift of the
washout curve compared with the control curve examined in
parallel in each experiment as seen in Fig. 4. A greater shift
represents shorter duration ligands, and smaller shifts represent
longer duration ligands. Values shown are means 6 SEM of n separate
experiments (n).
Figure 5. A) 3H-cAMP accumulation in CHO-b1 cells in response to NDD-713 and -825. Bars represent basal
3H-cAMP
accumulation, in response to 10 mM isoprenaline alone, and in response to 10 mM carvedilol alone. Data points are means 6 SEM
of triplicate determinations, and these single experiments are representative of 8 separate experiments in each case. B) CRE-
SPAP production in CHO-b1 cells in response to NDD-713 and -825. Bars represent basal CRE-SPAP production, in response to
10 mM isoprenaline alone, and in response to 10 mM carvedilol alone. Data points are means 6 SEM of triplicate determinations
and are representative of 5 separate experiments in each case. C) Basal and ERK1/2 MAPK activation in CHO-b1 cells in
response to phorbol ester, carvedilol, NDD-713, and -825 (5 min incubation). Bars are means 6 SEM of triplicate determinations.
This single experiment is representative of 4 separate experiments.
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3H-cAMPaccumulation orCRE-SPAPgene transcription
responses to a wide range of different ligands (45, 47).
Other GPCR and ion channel effects
To assess potential off-target effects, CGP20712A, LK204-
545, NDD-713, and -825 binding was assessed by using
the Cerep in vitro pharmacology profiling service in a di-
verse panel of 80 receptors and ion channels (Fig. 6).
Considerably more binding to other targets (off-target
effects) was observed with CGP20712A and LK204-545
compared with NDD-713 or -825. Where NDD-713
or -825 receptor binding inhibition exceeded 50%,
concentration–response experiments were conducted. Ki
values obtained were as follows: NDD-713: Ki (5-HT2A),
Figure 6. Receptor selectivity of CGP20712A (at 10 mM; A), LK204-545 (at 10 mM; B), NDD-713 (at 4.8 mM; C), and -825 (at
2.4 mM; D). The compounds were assayed against the receptors listed in duplicate and average values are shown. Values for b-ARs
are shown as black circles, those for receptors with .50% inhibition as red circles, those in the range of 30–50% inhibition as
orange circles, and those with ,30% inhibition as open circles. GPCRs: adenosine (A1, A2, A3), adrenoceptor (a1, a2, b1, b2),
angiotensin (AT1, AT2), benzodiazepine, central and peripheral (cBZD, pBZD), bombesin (BB), bradykinin (B2), chemokine
(CGPR, CXCR2, CCR1), cannabinoid (CB1), cholecystokinin (CCK1, CCK2), cytokine (TNF-a), dopamine (D1, D1S, D3, D4.4,
D5), endothelin (ETA, ETB), GABA, galanin (GAL1, GAL2), histamine (H1, H2), melanocortin (MC4), motilin (MT1),
muscarinic acetylcholine (M1, M2, M3, M4, M5), neurokinin (NK1, NK2, NK3), neuropeptide Y (Y1, Y2), neurotensin (NTS1),
nociception (NOP), opioid (DOP, KOP, MOP), prostaglandin (EP2, EP4, IP), pituitary adenylate cyclase-activating polypeptide
(PAC1), purinergic (P2X, P2Y), serotonergic (5-HT1A, 5-HT1B, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT3, 5-HT5A, 5-HT-6, 5-HT7),
s (s, PCP), somatostatin (SST), thromboxane (TP), vasoactive intestinal polypeptide (VPAC1), vasopressin (V1A). Ion channels:
calcium channel L verapamil site (Ca2+ Ch), potassium channel (KV Ch), sodium channels (SKCa Ch, hERG membrane
preparation, Na+ Ch site 2), chloride channel (Cl2 Ch GABA-gated), Tyr kinase receptor (PDGF). Nuclear hormone receptors:
glucocorticoid (GR), peroxisome proliferator (PPARg). Monoamine transporter: noradrenaline (NE Tr), dopamine (D Tr),
serotonin (5-HT Tr).
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7.7 mM; Ki (5-HT2B), .10 mM; Ki (noradrenaline trans-
porter), 2.8 mM; Ki (dopamine transporter), 0.8 mM; and
NDD-825: Ki (5-HT2A), 5.8 mM.
In vitro absorption, distribution, metabolism and
elimination of NDD-713 and -825
In vitro disposition properties of NDD-713 and -825 were
assessed in terms of solubility, lipophilicity, protein
binding, cell permeability,metabolic stability, and P450
metabolism (Table 5). Both compounds are basic, dis-
play good pH-dependent aqueous solubility, and have
comparatively low lipophilicity, plasma binding, and
intrinsic clearance in both rat and human liver micro-
some and hepatocyte preparations. NDD-713 showed
high and NDD-825 intermediate apical-to-basolateral
membrane permeability in the bidirectional CaCo-2
assay, without pronounced efflux of either compound.
NDD-713 was metabolized predominantly by CYP3A4
and CYP2A6 isoforms, whereas NDD-825 was metab-
olized mainly by CYP3A4 and CYP2D6 isoforms. Nei-
ther compound inhibited the activity of a panel of P450
enzymes.
In vivo pharmacology of NDD-713
and -825
PK analysis
As the in vitro properties of NDD-713 and -825 (receptor
affinity anddispositionproperties)were similar to those of
bisoprolol (57), similar dosing levels were administered to
rats. After a single dose of 20 mg/kg, p.o., the plasma fu
level of bisoprolol exceeded the b2-AR Kd value for.5 h,
whereas those of NDD-713 and -825 never reached the
b2-AR Kd (Fig. 7). PK analysis showed that bisoprolol
was a short-acting agent, whereas NDD-825, in par-
ticular, revealed slow oral absorption and elimination
alongside a large volume of distribution and, thus, was
present at therapeutic concentrations for considerably
longer (Fig. 7 and Tables 5 and 6).
In vivo b1- vs. b2-selectivity—intravenous studies
To assess b1-selectivity in vivo, compounds were admin-
istered to conscious rats, and HR (b1) and HQC (b2) were
monitored (51). Infusionof increasing concentrationsof the
nonselective b-AR agonist isoprenaline resulted in dose-
dependent increases of HR and HQC (Fig. 8). Infusion
of CGP20712A suppressed both basal and isoprenaline-
stimulated HR, with no significant reduction of HQC,
whereas ICI118551 suppressed a isoprenaline-induced
increase inHQCbutnotHR (Fig. 8). Bisoprolol (moderate
b1-selectivity at rat b-ARs and low b1-selectivity at hu-
man b-ARs; Table 1) reduced basal and isoprenaline-
induced HR responses but also suppressed the HQC
response. NDD-713 and -825 suppressed basal and
isoprenaline-induced HR but had no effect on HQC
responses, which confirmed their high b1-selectivity.
These effects were still visible at 4.0–5.5 h (3 h after i.v.
infusion finished) and suppression of basal activity was
also observed at 24–25 h (23–24 h after intravenous in-
fusion finished),whichwas inkeepingwith the longerPK
clearance of NDD-713 and -825.
In vivo b1- vs. b2-selectivity—oral studies
NDD-825 was administered by oral gavage (Fig. 9). At
1 mg/kg, NDD-825 caused a small but significant
lowering of basal HR. This was more pronounced on
TABLE 5. In vitro disposition properties of NDD-713 and -825
Parameter Assay Units NDD-713 NDD-825
Lipophilicity Distribution coefﬁcient, pH 3 gLogDpH 3 1.7 1.5
Distribution coefﬁcient, pH 7.4 gLogDpH 7.4 2.3 2.0
Solubilitya Aqueous, at pH 2.0 Saq (mg/ml) .100 .100
Aqueous, at pH 6.5 Saq (mg/ml) 25–50 50–100
Permeabilitya Bidirectional CaCo-2 Papp, A-B (10
26 cm/s) 25 6 4 6.5 6 0.5
Mass balance A-B (%) 76 6 10 79 6 11
Efﬂux ratio Papp, B-A/Papp, A-B ,3 ,3
Protein binding Plasma protein PPB (%) 63.5 73.5
Human plasma fu 0.15 0.01
Rat plasma fu 0.16 0.11
Human liver microsomes fu 0.67 0.63
Metabolic stability Human liver microsomesb CLint (ml/min/mg) ,0.16 ,0.16
Rat liver microsomesb CLint (ml/min/mg) ,0.1 0.18 6 0.2
Human hepatocytesb CLint (ml/min/10
6 cells) ,6 6
Rat hepatocytesb CLint (ml/min/10
6 cells) minimal 5
Rat liver cytosolic fractionb CLint (ml/min/mg) ,1.4 ,1.4–1.7
Metabolisma P450 in vitro clearancec CLint (ml/min/pmol P450) 0.02,
d,g 0.07e,g 0.02,f,g 0.17e,g
P450 inhibitionh IC50 (mM) .20 .20
Values and ranges quoted are averages of 2 (or 3 where means 6 SD are shown) separate determinations. aThe hydrochloride salts of NDD-
713 and -825 were used. bIn the presence of NAD+, NADPH, or in the absence of cofactors. cAssayed: CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9,
CYP2C19, CYP2D6, CYP2E1, CYP3A4. dCYP2A6. eCYP3A4. fCYP2D6 and CYP2E1. gNDD-713 and -825 were not observed to be metabolized by other
P450 isoforms assayed. hCYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4/5.
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subsequent days (at doses of 3 and 10 mg/kg), as was
the reduction in isoprenaline-stimulated HR. No sig-
nificant changes in HQC responses to isoprenaline
were recorded at any dose level.
Safety pharmacology and 7-d toxicology study
NDD-713 and -825 showed no cytotoxic effects in HepG2
cell viability assays even at the limits of aqueous
solubility. They had no affinity for the hERG channel
(at concentrations .3000-fold b1-AR affinity) and
only blocked the hERG potassium current at high con-
centrations (IC50 . 10 mM). Neither compound dis-
played genotoxicity at concentrations of #10 mM in
Ames tests. In the 7-d repeat-dose oral rat toxicology
study, NDD-825 was well tolerated at the highest dose
tested (300 mg/kg once daily) without any macro- or
microscopic clinical changes at autopsy. The most sig-
nificant change was a dose-related increase in triglycer-
ides at the top dose, which is a well-recognized effect of
b-blockers (58); however, the maximum tolerated dose
was not achieved and is therefore .300 mg/kg daily.
DISCUSSION
b-Blockers are important for reducing mortality in car-
diovascular disease. Although clinical studies have sug-
gested that b-blockers are associated with a reduction in
lung function in thegeneralpopulation (14),b-blockers are
well tolerated by most people. However, current clinical
b-blockers are poorly b1-selective and risk bronchospasm
and the loss of effectiveness of b2-agonist rescue (13), and,
thus, are contraindicated in patientswith asthma (25). This
poor selectivity also underlies safety concerns about
b-blockers in two other cardiovascular high-risk groups:
patientswithCOPD (bronchospasm)and those peripheral
vascular disease (b2-mediated vasoconstriction).
CGP20712A and LK204-545 are highly b1-selective
b-blockers, but neitherwere developed into clinical drugs.
CGP20712A interacts with many other receptors (Fig. 6),
and LK204-545 has significant partial agonism, which in-
creasesHR in rats (42).As there are currently no highlyb1-
selective ligands without these problematic properties,
we aimed to develop these novel ligands.
NDD-713 and -825 had high affinity for human b1-
AR and low affinity for human b2- and b3-ARs in two
directmeasures of affinity,which gave highb1-selectivity
compared with clinical b-blockers. NDD-713 and -825
also had longer durations of action at b1-AR than did
bisoprolol, although these were shorter than those of
nebivolol and carvedilol. CGP20712A and LK204-545
bound to a significant number of other targets, whereas
NDD-713 and -825 had poor affinity formost other GPCRs
and ion channels. The highest off-target affinity was for
the 5-HT2A GPCR for which b1-selectivity over the
5-HT2A receptor was 510-fold for NDD-713 and 1115-
fold for NDD-825. Unlike NDD-825, -713 also had some
affinity for the noradrenaline transporter (b1-AR vs.
noradrenaline transporter selectivitywas185-fold) and the
dopamine transporter (b1-AR vs. dopamine transporter
selectivity was 53-fold); therefore, NDD-825 has a clean
off-target profile.
Having established high b1-selectivity in vitro, we in-
vestigated in vivo selectivity by using the conscious, freely
moving ratmodel thatwas previously used to distinguish
b1- and b2-selective compounds (51). Here, HR responses
are purely b1 mediated, whereas HQC responses are
purely b2 mediated. Intravenous NDD-713 and -825
both reduced basal and isoprenaline-stimulated HR but
Figure 7. PK proﬁles of bisoprolol (A), NDD-713.HCl (B), and
-825.HCl (C) after single bolus intravenous or oral. administration
of compounds to rats. Plasma drug levels were corrected for plasma
protein binding (see Table 5). Plasma fu levels of compounds are
plotted as a function of time postadministration (values are
means 6 SD; n = 3). Concentrations corresponding to human
and rat b-AR Kd values of the 3 compounds are shown as
colored lines. Thus, to be effective, drug levels need to be
above the blue lines to achieve b1-blockade, but below the red
lines to avoid b2-blockade.
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didnot reduceHQC (Fig. 8),which suggestedno blockade
of rat vascular b2-ARs. As this may be considered a sur-
rogate marker for b2-AR interaction in airways, NDD-713
and -825 affinity was also determined in human bronchial
smoothmuscle cells, themain target ofb2-agonist therapy in
asthma and COPD. Here, NDD-713 and -825 affinity for
native human b2-AR was poor. Overall, these studies
confirmed the highly b1-selective natures of NDD-713
and -825.
Previous studies have shown that the degree of
partial agonism observed in CHO-b1 cells directly re-
flects the amount of b1-mediated partial agonism (in-
crease in HR) observed in rats (51). Thus, xamoterol
and bucindolol, with substantial b1-mediated partial
agonism, stimulate HR, but carvedilol (lower par-
tial agonism in CHO-b1 cells) and bisoprolol (no partial
agonism) reduce HR (51). Of the 4 b-blockers that
similarly reduce mortality in heart failure (7), carve-
dilol has the highest degree of partial agonism, and
bisoprolol and metoprolol have no agonism or bias
agonism at all. Thus, intrinsic activity that is low, equal
to, or (ideally) below that of carvedilol is required, but
the presence or absence of bias is not important. In
CHO-b1 cells, NDD-713 and -825 did not stimulate any
agonist response at cAMP, CRE-gene transcription
(a sensitive readout of both cAMP and ERK1/2MAPK),
or by directly measuring ERK1/2 MAPK, which sug-
gests no agonism or biased agonism. In rats, NDD-713
and -825 reduced both basal and isoprenaline-stimulated
HR, which once again confirmed no partial agonism
(ISA). Both in vitro and in vivo studies, therefore,
demonstrate that NDD-825 and -713 are neutral an-
tagonists and, thus, have an efficacy profile similar to
that of bisoprolol, metoprolol, and CGP20712A, rather
than carvedilol.
To assess pharmacologic activity by the oral route,
NDD-713, -825 and bisoprolol were administered by oral
gavage to lightly sedated rats and measurements taken
once rats were fully recovered. All 3 compounds caused a
reduction of basal and isoprenaline-stimulated HR, which
confirmed good oral bioavailability. For NDD-825, where
multipledifferentdoseswere administered, the reduction in
basal and isoprenaline-stimulatedHRwas dose dependent,
and a reduction in basal HR was observed the following
day, which suggested a long duration of action.
This longer duration of action (compared with
bisoprolol) was also observed in rat PK studies. After
20 mg/kg, p.o., plasma fu level of bisoprolol exceeded
the b2-AR Kd value for .5 h (Fig. 7). Bisoprolol-
mediated b2-AR blockade would likely be manifest for
5 h and the b1-AR–mediated effects would probably
last for;8 h. PK analysis of NDD-713 and -825 (20mg/
kg p.o.; Tables 5 and 6) revealed slow oral absorption
and elimination and large volumes of distribution;
therefore, they are likely to block b1-AR for much
longer periods (i.e., compare 10 h forNDD-713 and.24
h for NDD-825). Of importance, unbound plasma level
for both compounds never reached the respective
b2-AR Kd values at any time, and even at Cmax, were at
least 5-fold below b2-ARKd, which suggests thatb2-AR
blockade by NDD-713 or -825 is unlikely.
DrugmetabolismandPKproperties suggest thatNDD-
713 and -825 have excellent characteristics that lead to
extensive exposure at comparatively low doses, similar to
those of bisoprolol but with significantly slower clearance
and elimination. In addition, no safety problems were
identified, with no cytotoxic, genotoxic, or hERG binding
identified, and no problematic clinical chemistry, hemato-
logic, microscopic, or macroscopy organ changes identified
(7-d dosing, up to 300 mg/kg/d). NDD-713 and -825,
therefore, seem to be safe to administer to rats, even at
high doses.
Finally, to understandwhy such a highdegree ofb1- vs.
b2-selectivity is required to discriminate effects on
TABLE 6. PK properties of NDD-713 and -825 in rat after single bolus i.v. or p.o. administration (hydrochloride salt forms)
Parameter
Dose, i.v.
2 mg/kg 6 mg/kg 20 mg/kg
NDD-713 NDD-825 NDD-713 NDD-825 NDD-713 NDD-825
t1/2, app (h) 1.7 6 0.2 5.3 6 0.3 1.6 6 0.1 7.3 6 0.1 2.0 6 0 7.1 6 1.3
Plasma CLtotal (ml/min/kg) 62 6 4 54 6 2 43 6 1 59 6 1 51 6 2 55 6 1
Blood CLtotal (ml/min/kg) 51 6 3 39 6 1 36 6 1 42 6 1 42 6 1 39 6 1
Vss (L/kg) 4.3 6 0.4 6.0 6 0.5 3.6 6 0.2 5.0 6 0 4.2 6 0.2 4.7 6 0
AUC0-t (mM × h) 1.2 6 0.1 1.4 6 0 4.6 6 0.3 3.8 6 0.2 14.7 6 1.0 12.1 6 0.3
AUC0-t/dose [mM × h/(mg/kg)] 0.6 6 0.1 0.6 6 0 0.8 6 0 0.6 6 0 0.7 6 0 0.6 6 0
Dose, p.o.
Parameter
2 mg/kg 10 mg/kg 20 mg/kg
NDD-713 NDD-825 NDD-713 NDD-825 NDD-713 NDD-825
t1/2, app (h) n.d. 9.8 6 0.2 1.5 6 0 4.6 6 0.1 2.1 6 0 3.3 6 0.2
Cmax (mM) 0.2 6 0.1 0.1 6 0 2.1 6 0.6 0.8 6 0.1 2.0 6 0.1 1.4 6 0.3
tmax (min) 30 6 0 83 6 70 45 6 15 45 6 25 45 6 15 186 6 64
AUC0-t (mM × h) 0.6 6 0.2 0.4 6 0.1 5.1 6 0.2 3.0 6 0.4 6.3 6 0.3 11.9 6 3.0
AUC0-t/dose [mM × h/(mg/kg)] 0.4 6 0.1 0.2 6 0 0.5 6 0.1 0.3 6 0.1 0.3 6 0 0.5 6 0.2
F (%) 50 6 11 32 6 5 77 6 3 45 6 6 44 6 1 89 6 24
Values shown are means 6 SD (n = 3). N.d., not determined.
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Figure 8. Selectivity of various
b-blockers in vivo. Responses to iso-
prenaline before and after adminis-
tration of intravenous saline or
b-blockers in conscious, atropine-
treated, freely moving rats. Abso-
lute values for HR and HQC were
measured before (ﬁrst value of
each linked series) and at the end
of 3-min infusions of isoprenaline
(12, 40, and 120 ng/kg/min;
remaining 3 values in each linked
series). Isoprenaline was adminis-
tered before (control, solid circles),
during (open circles), 3–4 h after
(solid triangles), and 23–24 h after
(open triangles) the intravenous in-
fusion of saline (0.1 ml/kg bolus;
0.4 ml/kg/h infusion; A), CGP20712A
(200 mg/kg bolus; 100 mg/kg/h in-
fusion; B), ICI118551 (2 mg/kg bolus;
1 mg/kg/h infusion; C), and bisopro-
lol (2 mg/kg bolus; 1 mg/kg/h
infusion; D), NDD-713.HCl (2 mg/kg
bolus: 1 mg/kg/h infusion; E ),
and NDD-825.HCl (2 mg/kg bolus;
1 mg/kg/h infusion; F). Values are
means 6 SEM (n = 4). *P , 0.05 vs.
baseline before b-blocker; #P , 0.05
vs. isoprenaline maximum value be-
fore b-blocker (Quade test).
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cardiovascular and respiratory function,we calculated the
SIs of NDD-713 and NDD-825 and compared these with
those of bisoprolol. NDD-713 andNDD-825 have high b1-
AR binding selectivity at the receptor level (SI1; Table 7).
Weassessed the relative in vivo receptor occupancies (F) of
heart b1-AR and lung b2-AR as a function of unbound
drug levels in plasma for bisoprolol. Bisoprolol plasma
concentrations, measured in humans after 10 mg/d
bisoprolol, p.o., were obtained frompublished data (59,
60) to yield an SI (SI2; Table 7) that takes into account
relative receptor occupancies and fu of drug in plasma at
steady state (Cssf). For bisoprolol, with 43- to 69-fold
b1-AR selectivity at the receptor level (SI1), the apparent
b1-AR selectivity is reduced to 6-fold (SI2) when taking
into account in vivo receptor occupancy.
A PK–pharmacodynamic model (23, 54) was then
applied that considers relative b-AR affinity, receptor
occupancy, and relative receptor numbers in target
organs (61) and how receptor responses are actually
transduced to the pharmacologic responses [i.e., re-
duction of exercise-induced HR for b1-AR (62) and re-
duction in lung function (FEV1) for b2-AR (63)]. We
calculated a third SI (SI3; Table 7) that expresses selec-
tivity in terms of in vivo pharmacologic responses (E )
according to a ternary complex model (23, 54). We thus
determined an SI3 value of 4 for bisoprolol. It is clear
that with such a low in vivo pharmacologic selectivity,
bisoprolol could cause bronchospasm in susceptible
individuals.
We used the known ratio between bisoprolol exposure
(Cssf) at an efficacious dose (10 mg/d, p.o., which lowers
exercise-induced HR in humans) and receptor affinity
(Kdb1-AR) to estimate SIs for NDD-713 and NDD-825
(Table 7). Much higher indices (67- to 81-fold) were
obtained for NDD compounds, which suggests greater in
vivo selectivity than bisoprolol. The results demonstrate
that to obtain significant separation of in vivo pharmaco-
logic responses with respect to cardiac and respiratory
function, high selectivity with regard to binding to b1-AR
vs. b2-AR is required.
CONCLUSIONS
NDD-713 and, in particular, NDD-825 are high-affinity,
b1-selective ligands that are devoid of ISA, off-target effects,
and toxicology issues, but with good PK–pharmacody-
namic and absorption, distribution, metabolism and elimi-
nation properties that maintain b1-selectivity in conscious
animals. These ligands are therefore promising candidates
for the development of b-blockers devoid of b2-AR–
mediated adverse effects of bronchospasm and vasocon-
striction and, thus, may prove beneficial in patients with
concomitant cardiovascular and respiratory disease or limb
ischemia (peripheral vascular disease).
Figure 9. Responses to isoprenaline before and after admin-
istration of b-blockers in conscious, atropine-treated, freely
moving rats. Absolute values for HR and HQC were measured
before (ﬁrst value of each linked series) and at the end of 3-min
infusions of isoprenaline (12, 40, and 120 ng/kg/min;
remaining 3 values in each linked series). Isoprenaline was
administered before (control, solid circles), 1 h (open circles),
and 3 h (open triangles) after NDD-825.HCl, p.o. at a dose of
1 mg/kg (d 1), 3 mg/kg (d 2), and 10 mg/kg (d 3). Values are
means 6 SEM (n = 3 rats). *P , 0.05 vs. baseline before
b-blocker; #P , 0.05 vs. isoprenaline maximum value before
b-blocker (Quade test).
TABLE 7. Comparison SIs in terms or receptor binding (SI1), receptor occupancy (SI2), and pharmacological response (SI3) for bisoprolol, NDD-
713, and -825
b-Blocker SI1a (in vitro binding)
a
SI1b (in vitro inhibition of
functional response)b
SI2 (in vivo receptor
occupancy)c
SI3 (in vivo pharmacologic
response)d
NDD-713 589 1202 67 67
NDD-825 1023 1738 115 81
Bisoprolol 43 69 6 4
aSI1a = Kd,b2/Kd,b1 (Kd values from
3H-CGP12177 whole-cell binding; Table 1). bSI1b = Kd,b2/Kd,b1 (Kd values from antagonism of cimaterol-
induced 3H-cAMP accumulation; Table 2). cSI2 = Fb1/Fb2 = (Kd,b2 + Cssf)/(Kd,b1 + Cssf), where F is the receptor occupancy at the bARs, and Cssf
values refer to unbound drug levels in plasma at steady state upon once-daily oral dosing (Kd values from Table 1).
dSI3 = Eb1/Eb2, where Eb1 and
Eb2 refer to effects on exercise HR and on FEV1 under steady-state conditions after drug administration, respectively.
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